PINP as serum marker of metastatic spread to the bone in breast cancer patients

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1491-1499

  Lüftner, Diana ^a   Jozereau, D ^a   Schildhauer, S ^a   Geppert, R ^a   Muller C ^a   Fiolka, G ^a   Wernecke, K D ^a   Possinger, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bone metastases; Breast cancer; Crosslaps; Osteocalcin; PINP

Indexed keywords

AMINO TERMINAL PROPEPTIDE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; AUTOANALYZER; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; BONE SCINTISCANNING; BREAST CANCER; CANCER ADJUVANT THERAPY; CHEMOLUMINESCENCE; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ELECTROCHEMICAL ANALYSIS; ELECTROCHEMOLUMINESCENCE IMMUNOASSAY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OSSIFICATION; PATIENT MONITORING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SOFT TISSUE METASTASIS; TUMOR VOLUME;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 21244432764     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Wada N, Fujisaki M, Ishii S, Ikeda T and Kitajima M: Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 8(2): 131-137, 2001.
2. Moro L, Gazzarrini C, Crivellari D, Galligioni E, Talamini R and de Bernard B: Biochemical markers for detecting bone metastases in patients with breast cancer. Clin Chem 39(1): 131-134, 1993.
3. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M et al: Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45(8 Pt 1): 1240-1247, 1999.
4. Blomqvist C, Elomaa I, Virkkunen P, Porkka L, Karonen SL, Risteli L et al: The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. Cancer 60(12): 2907-2912, 1987.
5. Lacroix M, Marie PJ and Body JJ: Protein production by osteoblasts: modulation by breast cancer cell-derived factors. Breast Cancer Res Treat 61(1): 59-67, 2000.
6. Berruti A, Torta M, Piovesan A, Raucci CA, Orlandi F, Panero A et al: Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res 15(6B): 2871-2875, 1995.
7. Koizumi M, Yonese J, Fukui I and Ogata E: The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87(4): 348-351, 2001.
8. Tahtela R and Tholix E: Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 16(4B): 2289-2293, 1996.
9. Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P and Risteli J: Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 32A(7): 1166-1170, 1996.
10. Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S and Elomaa I: Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br J Cancer 78(2): 240-245, 1998.
11. de la PC, Castro-Errecaborde NA, Traba ML, Mendez-Davila C, Garcia-Moreno C, Rodriguez DA et al: Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331(1-2): 45-53, 2003.
12. Koizumi M, Yonese J, Fukui I and Ogata E: The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87(4): 348-351, 2001.
13. Bonde M, Qvist P, Fledelius C, Riis BJ and Christiansen C: Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40(11 Pt 1): 2022-2025, 1994.
14. Body JJ, Dumon JC, Gineyts E and Delmas PD: Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75(3): 408-412, 1997.
15. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE and Delmas PD: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82(4): 858-864, 2000.
16. Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW et al: Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol 24(7): 1211-1217, 1988.
17. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE and Delmas PD: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82(4): 858-864, 2000.
18. Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW et al: Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol 24(7): 1211-1217, 1988.
19. Tahtela R and Tholix E: Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 16(4B): 2289-2293, 1996.
20. Koizumi M, Yonese J, Fukui I and Ogata E: The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87(4): 348-351, 2001.
21. Koizumi M, Yonese J, Fukui I and Ogata E: Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 167(4): 1863-1866, 2002.
22. Jensen BV, Johansen JS, Skovsgaard T, Brandt J and Teisner B: Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. Int J Cancer 98(4): 582-589, 2002.
23. Jukkola A, Bloigu R, Holli K, Joensuu H, Valavaara R, Risteli J et al: Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Anticancer Res 21(4B): 2873-2876, 2001.